



## ASX Release

### Appendix 4C – Q4 2024 Quarterly Cash Flow Report

24 January 2025 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 December 2024 (Q4 24) and provided an update on business activities.

#### Financial Highlights

Oneview's cash balance on 31 December 2024 was €13.8 million (A\$23.2m).

The Company raised additional equity capital during the quarter, including the placement of CHESS depositary interests over fully paid ordinary shares in the Company (CDIs) to institutional and sophisticated investors, which raised A\$20m in gross proceeds on 21 November 2024. The Company also completed an over-subscribed Security Purchase Plan (SPP) in December 2024 which raised A\$3.0m in gross proceeds. The aggregate net proceeds of approximately €13.3 million (approximately A\$22.0 million) strengthens the balance sheet as deployment of the direct pipeline of contracted beds continues and as sales under the recently extended and expanded Baxter partnership ramps up. The proceeds will also fund Oneview's critical growth initiatives related to its AI strategy and internal configuration tooling to enable more efficient deployment at scale.

The Company had a net operating cash outflow of €4.1m during the quarter compared to an outflow of €0.1 million in the same quarter of the prior year. The higher outflow is primarily due to the timing of customer receipts, with two large customer receipts totalling over €2 million in aggregate received during the first weeks of January 2025. Product manufacturing and operating costs were higher in the quarter due to the payment of €386,000 for the expedited delivery of additional OEM hardware from a US supplier that manufactures in China, to mitigate against the risks of changes in global tariffs or delayed deliveries because of these possible changes. Marginally higher staff and admin costs for the quarter also contribute to the higher outflow as the Company resources the fulfilment of recent new signings and the Baxter pipeline.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €176,000 (A\$287,000).

## **Operational Activities**

### *Baxter Partnership*

As previously announced, Oneview signed a 2-year extension to Oneview's Value-Added Reselling Agreement with Baxter International, Inc. ("Baxter"), until June 2027 during the quarter. We continue to see growing momentum in this partnership with progress in product innovation and integration as well as sales opportunities and pipeline advancement with Oneview receiving POs from three new logos through the Baxter channel and one direct new logo during the quarter.

### *Direct Sales*

Contracted beds increased by 23% during 2024 from 15,821 to 19,429. Live beds also increased by 23% during 2024 from 10,151 to 12,514. Note this live bed number is 770 beds or 7% ahead of the installation burn up forecast provided in the HY2024 earnings release. Alongside the significant momentum from the Baxter partnership, Oneview's record direct sales pipeline positions the company for significant growth in its contracted beds and its revenues during 2025.

### *Customer Implementations and Expansions*

The Company continues its implementations in facilities contracted under recent agreements:

- Deployments of the core platform, the digital door sign and the digital whiteboard continued during the fourth quarter of 2024 at Inova Health under the Master Services Agreement which was signed in April 2024. A purchase order was recently received for another 316 beds which includes our core platform and the digital whiteboard which we expect to deploy during the first half of 2025.
- The deployment project at the Children's Hospital of Orange County also commenced during the quarter, where Oneview's new product, MyStay Mobile, will be deployed alongside in-room televisions across inpatient and outpatients points of care.
- A 235-bed deployment was completed at Mercy Ardmore in Oklahoma as part of the continued roll-out across a number of Mercy Health System sites.

Incremental deployments were also completed at existing customers during the quarter including UCSF, NYU and the University of Miami health systems.

2024 revenue was impacted by the postponement of projects by a large customer due to corporate activity and by construction delays in the Children's Hospital Ireland.

### *Outlook*

CEO James Fitter commented, "With the unwavering support of our shareholders during the recent capital raise, we are uniquely positioned among our competitors as the most trusted and reliable care experience platform on the market. We can provide not just the product innovation and scalability but also the balance sheet strength to ensure we are the partner of choice for the world's most discerning healthcare systems."

Mr. Fitter added "We are very well positioned to exploit the significant commercial traction we are gaining in the market through our own direct sales channels and through the Baxter partnership during 2025. We look forward to the year ahead with confidence and excitement".

This announcement has been approved for release by the board of Oneview Healthcare plc.

**About Oneview Healthcare plc**

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Oneview Healthcare PLC

**ABN**

610 611 768

**Quarter ended ("current quarter")**31<sup>st</sup> December 2024

| <b>Consolidated statement of cash flows</b>                |  | <b>Current quarter<br/>€'000</b> | <b>Year to date (12<br/>months)<br/>€'000</b> |
|--|--|----------------------------------|---|
| <b>1. Cash flows from operating activities</b>             |  |                                  |   |
| 1.1 Receipts from customers                                |  | 1,525                            | 9,471   |
| 1.2 Payments for   |  |                                  |   |
| (a) research and development                               |  | -                                | -   |
| (b) product manufacturing and operating costs              |  | (1,598)                          | (4,613)                                       |
| (c) advertising and marketing                              |  | (251)                            | (645)   |
| (d) leased assets  |  | -                                | -   |
| (e) staff costs  |  | (3,025)                          | (11,541)                                      |
| (f) administration and corporate costs                     |  | (1,117)                          | (3,833)                                       |
| 1.3 Dividends received (see note 3)                        |  | -                                | -   |
| 1.4 Interest received                                      |  | 1                                | 32  |
| 1.5 Interest and other costs of finance paid               |  | -                                | -   |
| 1.6 Income taxes (paid)/refunded                           |  | (43)                             | (91)  |
| 1.7 Government grants and tax incentives                   |  | -                                | 952   |
| 1.8 Other (working capital movements)                      |  | 433                              | (355)   |
| <b>1.11 Net cash from / (used in) operating activities</b> |  | <b>(4,075)</b>                   | <b>(10,623)</b>                               |

|            |   |            |              |
|------------|---|------------|--------------|
| <b>2.</b>  | <b>Cash flows from investing activities</b>           |            |              |
| 2.1        | Payments to acquire or for:                           |            |              |
|            | (a) entities  | -          | -            |
|            | (b) businesses  | -          | -            |
|            | (c) property, plant and equipment                     | (6)        | (50)         |
|            | (d) investments                                       | -          | -            |
|            | (e) intellectual property                             | -          | (306)        |
|            | (f) other non-current assets                          | -          | -            |
| 2.2        | Proceeds from disposal of:                            |            |              |
|            | (a) entities  | -          | -            |
|            | (b) businesses  | -          | -            |
|            | (c) property, plant and equipment                     | -          | -            |
|            | (d) investments                                       | -          | -            |
|            | (e) intellectual property                             | -          | -            |
|            | (f) other non-current assets                          | -          | -            |
| 2.3        | Cash flows from loans to other entities               | -          | -            |
| 2.4        | Dividends received (see note 3)                       | -          | -            |
| 2.5        | Other (provide details if material)                   | -          | -            |
| <b>2.6</b> | <b>Net cash from / (used in) investing activities</b> | <b>(6)</b> | <b>(356)</b> |

|             |   |               |               |
|-------------|---|---------------|---------------|
| <b>3.</b>   | <b>Cash flows from financing activities</b>   |               |               |
| 3.1         | Proceeds from issues of equity securities (excluding convertible debt securities)       | 13,944        | 13,944        |
| 3.2         | Proceeds from issue of convertible debt securities                                      | -             | -             |
| 3.3         | Proceeds from exercise of options   | -             | -             |
| 3.4         | Transaction costs related to issues of equity securities or convertible debt securities | (628)         | (628)         |
| 3.5         | Proceeds from borrowings  | -             | -             |
| 3.6         | Repayment of borrowings   | -             | -             |
| 3.7         | Transaction costs related to loans and borrowings                                       | -             | -             |
| 3.8         | Dividends paid  | -             | -             |
| 3.9         | Other (provide details if material)   | -             | -             |
| <b>3.10</b> | <b>Net cash from / (used in) financing activities</b>                                   | <b>13,316</b> | <b>13,316</b> |

|            |  |               |               |
|------------|--|---------------|---------------|
| <b>4.</b>  | <b>Net increase / (decrease) in cash and cash equivalents for the period</b> |               |               |
| 4.1        | Cash and cash equivalents at beginning of period                             | 4,734         | 11,542        |
| 4.2        | Net cash from / (used in) operating activities (item 1.11 above)             | (4,075)       | (10,623)      |
| 4.3        | Net cash from / (used in) investing activities (item 2.6 above)              | (6)           | (356)         |
| 4.4        | Net cash from / (used in) financing activities (item 3.10 above)             | 13,316        | 13,316        |
| 4.5        | Effect of movement in exchange rates on cash held                            | (136)         | (46)          |
| <b>4.6</b> | <b>Cash and cash equivalents at end of period</b>                            | <b>13,833</b> | <b>13,833</b> |

|            |   |                                  |                                   |
|------------|---|----------------------------------|-----------------------------------|
| <b>5.</b>  | <b>Reconciliation of cash and cash equivalents</b><br>at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | <b>Current quarter<br/>€'000</b> | <b>Previous quarter<br/>€'000</b> |
| 5.1        | Bank balances   | 13,826                           | 4,208                             |
| 5.2        | Call deposits   | 7                                | 526                               |
| 5.3        | Bank overdrafts   | -                                | -                                 |
| 5.4        | Other (provide details)   | -                                | -                                 |
| <b>5.5</b> | <b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>  | <b>13,833</b>                    | <b>4,734</b>                      |

|   |   |                                  |
|---|---|----------------------------------|
| <b>6.</b>   | <b>Payments to related parties of the entity and their associates</b>                   | <b>Current quarter<br/>€'000</b> |
| 6.1   | Aggregate amount of payments to related parties and their associates included in item 1 | 176                              |
| 6.2   | Aggregate amount of payments to related parties and their associates included in item 2 | -                                |
| <i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> |   |                                  |

|           |   |   |  |
|-----------|---|---|--|
| <b>7.</b> | <b>Financing facilities</b><br><i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i><br><i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>  | <b>Total facility<br/>amount at quarter<br/>end<br/>€'000</b> | <b>Amount drawn at<br/>quarter end<br/>€'000</b> |
| 7.1       | Loan facilities   | -   | -  |
| 7.2       | Credit standby arrangements   | -   | -  |
| 7.3       | Other (please specify)  | -   | -  |
| 7.4       | <b>Total financing facilities</b>   | -   | -  |
| 7.5       | <b>Unused financing facilities available at quarter end</b>   |   | -  |
| 7.6       | Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. |   |  |
|           |   |   |  |

|  |  |              |
|--|--|--------------|
| <b>8.</b>  | <b>Estimated cash available for future operating activities</b>  | <b>€'000</b> |
| 8.1  | Net cash from / (used in) operating activities (item 1.9)  | (4,075)      |
| 8.2  | Cash and cash equivalents at quarter end (item 4.6)  | 13,833       |
| 8.3  | Unused finance facilities available at quarter end (item 7.5)  | -            |
| 8.4  | Total available funding (item 8.2 + item 8.3)  | 13,833       |
| 8.5  | <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>  | 3.39         |
| <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i> |  |              |
| 8.6  | If item 8.5 is less than 2 quarters, please provide answers to the following questions:  |              |
| 8.6.1  | Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?  |              |
|  | Answer: N/a  |              |
| 8.6.2  | Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? |              |
|  | Answer: N/a  |              |
| 8.6.3  | Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?  |              |
|  | Answer: N/a  |              |
| <i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>   |  |              |

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....24 January 2025.....

Authorised by: ..... **BY THE BOARD** .....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.